Digital rheumatology in the era of COVID-19: results of a national patient and physician survey
Standard
Digital rheumatology in the era of COVID-19: results of a national patient and physician survey. / Kernder, Anna; Morf, Harriet; Klemm, Philipp; Vossen, Diana; Haase, Isabell; Mucke, Johanna; Meyer, Marco; Kleyer, Arnd; Sewerin, Philipp; Bendzuck, Gerlinde; Eis, Sabine; Knitza, Johannes; Krusche, Martin.
in: RMD OPEN, Jahrgang 7, Nr. 1, e001548, 02.2021.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Digital rheumatology in the era of COVID-19: results of a national patient and physician survey
AU - Kernder, Anna
AU - Morf, Harriet
AU - Klemm, Philipp
AU - Vossen, Diana
AU - Haase, Isabell
AU - Mucke, Johanna
AU - Meyer, Marco
AU - Kleyer, Arnd
AU - Sewerin, Philipp
AU - Bendzuck, Gerlinde
AU - Eis, Sabine
AU - Knitza, Johannes
AU - Krusche, Martin
N1 - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/2
Y1 - 2021/2
N2 - OBJECTIVE: To analyse the impact of the COVID-19 pandemic on rheumatic patients' and rheumatologists' usage, preferences and perception of digital health applications (DHAs).METHODS: A web-based national survey was developed by the Working Group Young Rheumatology of the German Society for Rheumatology and the German League against Rheumatism. The prospective survey was distributed via social media (Twitter, Instagram and Facebook), QR code and email. Descriptive statistics were calculated, and regression analyses were performed to show correlations.RESULTS: We analysed the responses of 299 patients and 129 rheumatologists. Most patients (74%) and rheumatologists (76%) believed that DHAs are useful in the management of rheumatic and musculoskeletal diseases (RMDs) and felt confident in their own usage thereof (90%; 86%). 38% of patients and 71% of rheumatologists reported that their attitude had changed positively towards DHAs and that their usage had increased due to COVID-19 (29%; 48%). The majority in both groups agreed on implementing virtual visits for follow-up appointments in stable disease conditions. The most reported advantages of DHAs were usage independent of time and place (76.6%; 77.5%). The main barriers were a lack of information on suitable, available DHAs (58.5%; 41.9%), poor usability (42.1% of patients) and a lack of evidence supporting the effectiveness of DHAs (23.2% of rheumatologists). Only a minority (<10% in both groups) believed that digitalisation has a negative impact on the patient-doctor relationship.CONCLUSION: The COVID-19 pandemic instigated an increase in patients' and rheumatologists' acceptance and usage of DHAs, possibly introducing a permanent paradigm shift in the management of RMDs.
AB - OBJECTIVE: To analyse the impact of the COVID-19 pandemic on rheumatic patients' and rheumatologists' usage, preferences and perception of digital health applications (DHAs).METHODS: A web-based national survey was developed by the Working Group Young Rheumatology of the German Society for Rheumatology and the German League against Rheumatism. The prospective survey was distributed via social media (Twitter, Instagram and Facebook), QR code and email. Descriptive statistics were calculated, and regression analyses were performed to show correlations.RESULTS: We analysed the responses of 299 patients and 129 rheumatologists. Most patients (74%) and rheumatologists (76%) believed that DHAs are useful in the management of rheumatic and musculoskeletal diseases (RMDs) and felt confident in their own usage thereof (90%; 86%). 38% of patients and 71% of rheumatologists reported that their attitude had changed positively towards DHAs and that their usage had increased due to COVID-19 (29%; 48%). The majority in both groups agreed on implementing virtual visits for follow-up appointments in stable disease conditions. The most reported advantages of DHAs were usage independent of time and place (76.6%; 77.5%). The main barriers were a lack of information on suitable, available DHAs (58.5%; 41.9%), poor usability (42.1% of patients) and a lack of evidence supporting the effectiveness of DHAs (23.2% of rheumatologists). Only a minority (<10% in both groups) believed that digitalisation has a negative impact on the patient-doctor relationship.CONCLUSION: The COVID-19 pandemic instigated an increase in patients' and rheumatologists' acceptance and usage of DHAs, possibly introducing a permanent paradigm shift in the management of RMDs.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - COVID-19
KW - Female
KW - Health Knowledge, Attitudes, Practice
KW - Humans
KW - Male
KW - Middle Aged
KW - Musculoskeletal Diseases/therapy
KW - Patient Acceptance of Health Care/statistics & numerical data
KW - Prospective Studies
KW - Rheumatologists/statistics & numerical data
KW - Surveys and Questionnaires
KW - Telemedicine
KW - Young Adult
U2 - 10.1136/rmdopen-2020-001548
DO - 10.1136/rmdopen-2020-001548
M3 - SCORING: Journal article
C2 - 33622673
VL - 7
JO - RMD OPEN
JF - RMD OPEN
SN - 2056-5933
IS - 1
M1 - e001548
ER -